U.S. Stock News

NYSE:LU
NYSE:LUConsumer Finance

Lufax Holding (NYSE:LU) TTM Net Loss Deepens To C¥3.9b Challenging Earnings Recovery Hopes

Lufax Holding (NYSE:LU) has just posted another tough set of FY 2025 numbers, with Q3 2024 revenue of C¥5.5b alongside a basic EPS loss of C¥1.12 and net income loss of C¥874.8m. The company has seen quarterly revenue move from C¥9.3b in Q2 2023 to C¥8.1b in Q3 2023, then to C¥5.5b in Q3 2024, while basic EPS shifted from a profit of C¥1.68 in Q2 2023 and C¥0.16 in Q3 2023 to losses across the last four reported quarters. At a share price of US$1.95 and with losses weighing on recent margins,...
NYSE:NSP
NYSE:NSPProfessional Services

Insperity (NSP) Q1 EPS Rebound Tests Bearish Margin Narratives

Insperity (NSP) opened 2026 with Q1 revenue of US$1.9b and basic EPS of US$0.88, alongside net income of US$33m. On a trailing twelve month basis, revenue stands at US$6.8b and basic EPS at a loss of US$0.66 tied to a net loss of US$25m. Over recent quarters the company has reported revenue between US$1.6b and US$1.9b, with quarterly basic EPS ranging from a profit of US$1.34 to a loss of US$0.88. This places the latest figures against a backdrop of shifting margins and profitability...
OTCPK:NTPI.F
OTCPK:NTPI.FReal Estate

Nam Tai Property (OTCPK:NTPI.F) Margin Collapse Challenges Prior Profitability Narrative

Nam Tai Property (OTCPK:NTPI.F) just wrapped up FY 2025 with Q4 revenue of US$16.4 million and a basic EPS loss of US$0.09, capping a trailing twelve month period where revenue reached US$48.0 million and basic EPS was essentially flat at US$0.00. Over the past few quarters, revenue has moved from US$7.8 million in Q1 2025 to US$14.2 million in Q2, US$9.7 million in Q3, and US$16.4 million in Q4. Quarterly EPS swung from a loss of US$0.09 in Q1 to a profit of US$0.23 in Q2 before returning to...
NYSE:KWR
NYSE:KWRChemicals

Quaker Chemical (KWR) Net Margin Collapse To 0.2% Tests Bullish Earnings Narrative

Quaker Chemical (KWR) opened 2026 with Q1 revenue of US$480.5 million and basic EPS of US$1.14, with the latest trailing twelve month figures showing revenue of about US$1.9 billion and basic EPS of US$0.25. Over recent quarters, revenue has moved from US$442.9 million and EPS of US$0.73 in Q1 2025 to US$444.1 million and EPS of US$0.80 in Q4 2024, before reaching US$480.5 million and EPS of US$1.14 in the latest quarter. This has occurred against a backdrop of trailing net income that has...
NYSE:HIPO
NYSE:HIPOInsurance

Hippo Holdings (HIPO) Earnings Swing To US$4.42 TTM EPS Challenges Bearish Narratives

Hippo Holdings (HIPO) opened 2026 with Q1 revenue of US$121.5 million and basic EPS of US$0.27, alongside trailing twelve month revenue of US$479.6 million and EPS of US$4.42. Over the past four reported quarters, revenue has moved from US$397.3 million to US$479.6 million on a trailing basis, while EPS shifted from a trailing loss of US$1.64 to EPS of US$4.42. This puts the focus on how durable that earnings profile really is. The latest quarter keeps attention squarely on margins and the...
NYSE:DY
NYSE:DYConstruction

Is It Too Late To Consider Dycom Industries (DY) After A 140% One Year Surge?

If you are wondering whether Dycom Industries is still reasonably priced after a strong run, or if the stock is starting to look stretched, this article walks through what the current market price could be implying. Dycom’s share price recently closed at US$433.60, with reported returns of 5.6% over the past week, 24.8% over the last month, 24.8% year to date, 140.2% over 1 year, 354.5% over 3 years and 339.1% over 5 years. Recent coverage has focused on Dycom’s role as a specialty...
NasdaqGS:TFSL
NasdaqGS:TFSLBanks

TFS Financial (TFSL) Q2 2026 High 27.3% Margin Tests Premium P/E Narrative

Latest quarterly snapshot TFS Financial (TFSL) has just posted Q2 2026 results with total revenue of US$85.2 million and basic EPS of US$0.08, setting the tone for how investors will read the latest quarter. The company has seen revenue move from US$77.6 million in Q2 2025 to US$85.2 million in Q2 2026, while quarterly EPS has ranged between about US$0.07 and US$0.09 over the last six reported periods. This gives a clear view of how the top and bottom line have tracked together. With trailing...
NYSE:ATR
NYSE:ATRPackaging

AptarGroup (ATR) Margin Compression Challenges Bullish Pharma Growth Narrative In Q1 2026

AptarGroup (ATR) opened 2026 with Q1 revenue of US$982.9 million and basic EPS of US$1.13, while trailing twelve month revenue stood at US$3.9 billion and EPS at US$5.93, setting a clear benchmark for the latest quarter against its recent run rate. Over the past five reported quarters, revenue has moved from US$887.3 million in Q1 2025 to US$982.9 million in Q1 2026, with quarterly EPS ranging between US$1.13 and US$1.95 over that stretch. This gives investors a consistent view of how the top...
NasdaqGS:BKR
NasdaqGS:BKREnergy Services

Is It Too Late To Look At Baker Hughes (BKR) After A 90% One-Year Rally?

If you are wondering whether Baker Hughes at around US$69.12 is still reasonable value or if you are arriving late to the story, this article will help you frame that question clearly. The stock has posted returns of 0.3% over 7 days, 14.6% over 30 days, 46.6% year to date and 90.1% over the last year, which naturally raises questions about how much of the value case is already reflected in the price. Recent coverage has focused on Baker Hughes as a key energy services name during a period...
NasdaqCM:VKTX
NasdaqCM:VKTXBiotechs

A Look At Viking Therapeutics (VKTX) Valuation As Phase 3 Obesity Program Reaches Key Enrollment Milestones

Viking Therapeutics (VKTX) has moved deeper into late stage obesity drug development, completing enrollment in its Phase 3 VANQUISH-1 and VANQUISH-2 trials for injectable VK2735 and outlining plans for an oral Phase 3 program. See our latest analysis for Viking Therapeutics. The wider Q1 loss, as R&D spending ramped for Phase 3 obesity programs, appears to be weighing on sentiment in the short term, with a 1 month share price return decline of 8.98% and a year to date share price return...
NYSE:ZETA
NYSE:ZETASoftware

Zeta Global Holdings (ZETA) Q1 Loss Tests Bullish Profitability Narratives

Zeta Global Holdings (ZETA) Q1 2026 earnings snapshot Zeta Global Holdings (ZETA) opened 2026 with Q1 revenue of US$396.3 million and a basic EPS loss of US$0.05 per share, while the trailing 12 month figures show US$1.4 billion of revenue and a net loss of US$23.2 million. Over the past five reported quarters, revenue has moved from US$264.4 million in Q1 2025 to US$396.3 million in Q1 2026, while basic EPS has ranged between a loss of US$0.10 and a profit of US$0.07 per share across that...
NYSE:MUX
NYSE:MUXMetals and Mining

Is It Too Late To Consider McEwen (MUX) After A 189% One Year Surge?

Wondering whether McEwen's current share price reflects its real worth, or if the stock is getting ahead of itself. The share price last closed at US$21.30, with returns of 14.0% year to date and 189.4% over the past year, while the last 7 days saw a 12.2% decline and the last 30 days were flat at a 0.5% decline. Recent coverage has focused on McEwen's strong one year return of 189.4%. This stands out against its more moderate 3 year and 5 year returns of 138.8% and 63.8%. This context...
NYSE:PDM
NYSE:PDMOffice REITs

Piedmont Realty Trust (PDM) Q1 FFO Profile Tests Bullish Turnaround Narratives

Piedmont Realty Trust (PDM) opened 2026 with Q1 revenue of US$143.3 million and basic EPS of a US$0.10 loss, while trailing 12 month revenue was US$565.6 million and EPS was a US$0.69 loss. Over the past year, the company’s quarterly revenue moved from US$142.7 million in Q1 2025 to US$143.3 million in Q1 2026, with basic EPS shifting from a Q1 2025 loss of US$0.08 per share to a Q1 2026 loss of US$0.10 per share as investors consider how these margins may influence any potential...
NYSE:CHE
NYSE:CHEHealthcare

Is It Time To Reconsider Chemed (CHE) After Recent 11.8% Share Price Jump?

Investors may be wondering whether Chemed, at around US$422 per share, still lines up with its underlying worth or if the recent price is out of step with fundamentals. Over the last month the stock is up 11.8%, even though the 1 year return sits at a 26.3% decline and the year to date return is roughly flat at a 0.4% decline. Recent coverage around Chemed has focused on its role in healthcare services and how investors are weighing that profile against a weaker 1 year share price...
NYSE:MHK
NYSE:MHKConsumer Durables

Mohawk Industries Q1 EPS Volatility Tests Bullish Margin Recovery Narratives

Mohawk Industries (MHK) opened 2026 with Q1 revenue of US$2.7 billion and basic EPS of US$1.91, setting the tone for how investors weigh the latest numbers against trailing profitability and growth expectations. Over the past few quarters, revenue has moved between US$2.5 billion in Q1 2025 and US$2.8 billion in Q2 2025, while basic EPS ranged from US$0.68 in Q4 2025 to US$2.35 in Q2 2025, providing a view of how earnings have tracked relative to a fairly steady top line. With trailing net...
NasdaqGS:LASR
NasdaqGS:LASRElectronic

nLIGHT Italy Expansion Deepens Ties To European Defense Laser Demand

nLIGHT (NasdaqGS:LASR) is expanding its operations in Torino, Italy to support rising regional demand for directed energy and high power laser solutions. The move is intended to serve European and allied customers with regionally tailored products and improve localization and supply chain resilience. This expansion marks a material step in nLIGHT's international build out and its focus on defense related laser technologies. For investors tracking nLIGHT, the expansion comes with the shares...
NasdaqCM:NXTT
NasdaqCM:NXTTSoftware

Next Technology Holding (NXTT) Posts US$105.9 Million Q1 Loss Reinforcing Bearish Narratives

Next Technology Holding (NasdaqCM:NXTT) opened 2026 with Q1 revenue of about US$0.5 million and a basic EPS loss of US$1.39 per share, alongside a net loss of US$105.9 million. Over recent quarters the company has seen revenue move from US$0 in Q1 2025 to US$9.8 million in Q4 2025 before landing at US$0.5 million in Q1 2026. EPS has swung from a very high profit of US$396.38 per share in Q1 2025 to a loss of US$1.39 in the latest quarter, setting a backdrop where reported margins look highly...
NYSE:BIPC
NYSE:BIPCGas Utilities

Brookfield Infrastructure Corp (BIPC) Q1 Loss Extends Earnings Concerns Despite Revenue Base

Brookfield Infrastructure (NYSE:BIPC) has opened 2026 with Q1 revenue of US$884 million and a basic EPS loss of US$0.93, setting the tone for another quarter where the income statement matters more than headline growth stories. Over the past year, quarterly revenue has ranged from US$866 million to US$956 million while EPS has swung between a gain of US$3.27 and a loss of US$4.01, highlighting how volatile profitability has been for shareholders watching margins. See our full analysis for...
NasdaqGS:BLKB
NasdaqGS:BLKBSoftware

Is It Time To Reassess Blackbaud (BLKB) After A Tough Year Of Share Price Losses

Wondering whether Blackbaud at around US$37.54 is a bargain or a value trap? This breakdown will help you size up what the current share price really reflects. The stock has been broadly flat over the last month at around 0.0%. However, that sits against a much tougher backdrop with a 36.9% decline year to date and a 38.9% decline over the past year. Those longer term returns mean many holders are sitting on losses, which often pushes valuation questions to the front of investors' minds...
NasdaqCM:PDEX
NasdaqCM:PDEXMedical Equipment

Pro Dex (PDEX) One Off Gain Inflated Earnings Challenges Bullish Narratives

Pro-Dex (PDEX) has put up a solid Q3 2026 print, with revenue of about US$19.9 million and basic EPS of roughly US$1.23, against a trailing twelve month backdrop where earnings grew 28.1% year over year and net profit margin sat at 16.1%. Over recent quarters the company has seen revenue move from around US$17.4 million in Q3 2025 to US$19.9 million in Q3 2026, while quarterly basic EPS ranged between roughly US$0.37 and US$1.43 over that stretch, giving a clear view of how revenue and per...
NYSE:AIG
NYSE:AIGInsurance

AIG (AIG) Net Margin Improvement In Q1 2026 Tests Persistent Risk Concerns

American International Group (AIG) opened 2026 with Q1 results that put the focus squarely on the income statement, as revenue came in at US$6.7b and basic EPS landed at US$1.42 on net income of US$763m. The company has seen revenue move from US$6.5b in Q1 2025 to US$6.7b in Q1 2026, while basic EPS over that stretch ranged from US$1.18 in Q1 2025 to US$1.42 in the latest quarter. This sets the stage for investors to weigh these headline figures against a backdrop of improving trailing net...
NasdaqCM:OSPN
NasdaqCM:OSPNSoftware

OneSpan (OSPN) Q1 EPS Stability Tests Bearish Earnings Decline Narrative

OneSpan (OSPN) Q1 2026 earnings snapshot OneSpan (OSPN) has opened 2026 with Q1 revenue of US$65.9 million and basic EPS of US$0.31, setting the tone for investors assessing how the business is converting its software demand into bottom line results. Over the past year, the company has seen trailing twelve month revenue sit at US$245.8 million with basic EPS of US$1.84, alongside earnings growth of 20.4% and net margins at 28.5% compared to 24% a year earlier. This provides useful context for...
NasdaqGS:LPLA
NasdaqGS:LPLACapital Markets

LPL Financial Holdings (LPLA) Q1 EPS Strength Tests Margin And Volatility Concerns

LPL Financial Holdings (LPLA) opened 2026 with Q1 revenue of about US$4.8b and basic EPS of US$4.45, as investors weigh these headline figures against a reported net margin of 5% over the trailing 12 months that was affected by a US$732.0m one off loss. The company has seen quarterly revenue move from US$3.4b in Q4 2024 to US$3.6b in Q1 2025 and then to about US$4.8b in Q1 2026. Over the last six reported periods, trailing 12 month basic EPS has ranged from US$14.17 to US$11.25, placing...
NasdaqCM:JBIO
NasdaqCM:JBIOBiotechs

Jade Biosciences Reshapes Clinical Leadership As Valuation Debate Persists

Jade Biosciences (NasdaqCM: JBIO) appointed Edward R. Conner, M.D. as Chief Medical Officer. The company elevated Andrew King, M.D., Ph.D. to President, Research & Development. These leadership changes focus on clinical development, regulatory strategy, and R&D continuity for Jade's autoimmune pipeline. Jade Biosciences, listed on NasdaqCM under the ticker JBIO, is focused on developing therapies for autoimmune conditions, an area that continues to attract capital and partnerships across...